Acalabrutinib Shows Promise in CLL, Other Indications

New data are being presented at ASH 2021 regarding the durable efficacy of acalabrutinib in chronic lymphocytic leukemia.

In an interview with Pharmacy Times, Niko Andre, MD, PhD, global franchise head of hematology and immuno-oncology at AstraZeneca, discussed the promising recent findings for acalabrutinib (Calquence; AstraZeneca) in the treatment of chronic lymphocytic leukemia (CLL).

In the interview, Andre said acalabrutinib is a next-generation Bruton's tyrosine kinase (BTK) inhibitor. He also discussed new data presented at the American Society of Hematology 2021 Annual Meeting, safety and adverse effects data for acalabrutinib, and how pharmacists can manage treatment with the drug.